Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial.
Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials.
Journal of the European Academy of Dermatology and Venereology : JEADV·2019
Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials.
Journal of the European Academy of Dermatology and Venereology : JEADV·2017
Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
Journal of the European Academy of Dermatology and Venereology : JEADV·2017
Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials.
Journal of the European Academy of Dermatology and Venereology : JEADV·2017
Vasoactive intestinal polypeptide (VIP) in the male genitourinary tract: concentration and motor effect.
Investigative urology·1981
Effects of DES on the morphology of the lobes of the baboon prostate.
Investigative urology·1981
Nucleation kinetics in the calcium oxalate-sodium urate monohydrate system.
Investigative urology·1981
Plasma lipid bound sialic acid in patients with prostate and bladder cancer.
Investigative urology·1981
Triple drug chemotherapy in treatment of prostate adenocarcinoma Nb Pr A.I.-III.
Investigative urology·1981
A cautious use of sodium cellulose phosphate in the management of calcium nephrolithiasis.
Investigative urology·1981
Severe hypercalcemia in a patient with end-stage liver disease.
JCEM case reports·2026
UNC93B1 drives IL-6/STAT3-dependent tumor-macrophage crosstalk and epithelial-mesenchymal transition in breast cancer.
Frontiers in pharmacology·2026
Early esophageal squamous neoplasia and the microbiome: evidence, mechanisms, and early-detection potential.
Frontiers in microbiology·2026